Front Line Genomics invites you to their event

Liquid Biopsy ONLINE - Webinar 1: Designing Liquid Biopsy Assays for Real-World Use

About this event

Liquid Biopsy ONLINE – From Assay to Clinical Adoption 

Thursday 16th, 23rd & 30th July 2026 at 3pm BST | 4pm CEST | 10am EST 

Liquid biopsy is rapidly transforming how cancer is detected, monitored, and treated. While major progress has been made in identifying tumour-derived signals in blood, the central challenge now is translating these advances into robust, clinically deployable tools that improve patient outcomes. 

This three-part webinar series moves beyond the hype to focus on what it takes to bring liquid biopsy into routine clinical practice. Across the series, we will explore how assays are engineered to detect rare tumour signals, how emerging biomarker strategies are reshaping performance, and how these technologies are being validated and implemented in clinical trials and healthcare systems. 

Webinar 1: Designing Liquid Biopsy Assays for Real-World Use 

Thursday 16th July 2026 | 3pm BST | 4pm CEST | 10am EST 

Sponsored by Twist Bioscience 

As liquid biopsy applications expand into earlier cancer detection and increasingly challenging clinical settings, assay performance has never been more critical. This session will explore how researchers and technology developers are improving assay sensitivity through advances in sequencing strategies, target enrichment and workflow optimisation. It will also examine how assay design decisions impact reproducibility, scalability and suitability for downstream use in translational research and clinical studies.   

Key Takeaways 

  • How assay design, sequencing strategy, and bioinformatics impact sensitivity 
  • Methods for capturing and enriching low-frequency tumour signals
  • How design choices affect scalability and reproducibility in real-world settings

Talk 1: Implementing Liquid Biopsy in Paediatric Oncology: Balancing Breadth, Cost, and Clinical Utility 

  • Translating a liquid biopsy assay for paediatric oncology in the clinic: methods, timelines, barriers and constraints 
  • The challenge of rare, heterogeneous indications: selecting assays that capture key alterations in paediatric cancers 
  • Cost vs. coverage: navigating trade-offs between assay breadth and depth, rapid turnover, and limited healthcare budgets 

Alexandre Rouette, Clinical Specialist, CHU Sainte-Justine Children's Hospital 

Talk 2: Customizable Genomic Profiling of Cell-Free DNA for Oncology 

  • Highly sensitive cfDNA solutions for MRD detection and ultra-low frequency variant analysis 
  • Custom hybridization capture panels for personalized liquid biopsy and oncology assay development
  • Methylation enrichment workflows for epigenetic biomarker discovery and early cancer detection
  • Optimized workflows delivering uniform coverage, flexibility, and scalability for precision oncology research

James Flynn, Senior Staff Product Manager, Twist Bioscience 

Talk 3: Evaluating Whole Blood as an Alternative to Plasma for Liquid Biopsy Applications 

  • Performance of whole blood for ctDNA detection, including effects on sensitivity and reproducibility 
  • Impact of pre-analytical variables (e.g. sample handling, processing time) on assay performance  
  • Implications for assay design, scalability and implementation in clinical and research settings 

Maria Neofytou, Lecturer, University of Westminster 

Webinar 2: Beyond ctDNA – Evaluating the Next Generation of Liquid Biopsy Biomarkers 

Thursday 23rd July 2026 at 3pm BST/ 4pm CEST/ 10am EST  

Sponsored by Thermo Fisher Scientific 

This webinar will bring together academic, clinical and industry perspectives to examine whether next-generation liquid biopsy approaches are truly delivering on their promise. As new biomarker strategies such as fragmentomics, methylation and multi-modal assays rapidly emerge, which approaches are showing the greatest clinical value—and which still require further validation?   

Through real-world case studies and expert discussion, attendees will gain practical insight into the strengths, limitations and trade-offs of different biomarker strategies, including sensitivity, specificity, scalability and clinical utility, and what these advances could mean for the future of cancer detection and patient management. 

Key Takeaways 

  • How emerging biomarkers are being applied in liquid biopsy
  • The potential and limitations of multi-analyte approaches
  • How new biomarker strategies are being evaluated in clinical and translational settings

Talk 1: Rethinking Liquid Biopsy: From Targeted Panels to Multimodal Detection

  • Some targeted panels miss actionable variants – insights from ctDNA breast cancer diagnostics
  • Moving beyond mutations: integrating fragmentomics, epigenomics, and CNVs using low-pass WGS
  • Early evidence for sensitive detection in early-stage cancers

Ariane Hallermayr, Head of Research and Development, Medical Genetics Centre 

Talk 2: Expanding the Role of CTCs and Immune Cells in Cancer Detection and Monitoring  

  • The value of complementary biomarker strategies, including CTCs, immune cell signals and cfDNA, for improving cancer detection and monitoring.
  • How multi-omic approaches and AI can be used to integrate complex biological signals and generate more clinically meaningful insights  
  • Opportunities and challenges in moving beyond single-analyte liquid biopsy toward more comprehensive, integrated approaches 

Catherine Alix-Panabières, Professor of Oncology and Director of the Laboratory of Rare Human Circulating Cells, University of Montpellier  

Talk 3: Enhancing Signal Detection in Multi-Omic Spatial Analysis for Early Cancer Insights 

  • Strategies to improve signal-to-noise and combine fragmented molecular signals to enhance the reliability of multi-omic analyses 
  • The role of fragmentomics in enabling earlier cancer detection and providing sensitive markers of treatment response 
  • Opportunities and challenges in translating complex, integrated molecular signals into clinically actionable insights 

Dineika Chandrananda, Senior Bioinformatics Research Officer, Peter MacCallum Cancer Centre  

Webinar 3: From Trials to Routine Care: Making Liquid Biopsy Work in Practice  

Thursday 30th July 2026 at 3pm BST/ 4pm CEST/ 10am EST  

To realise the full potential of liquid biopsy, these technologies must be successfully integrated into clinical trials and healthcare systems. This requires evidence of clinical utility, clear regulatory pathways and practical strategies for implementation at scale. 

This interactive panel will bring together experts from academia, healthcare and industry to discuss what it will take for liquid biopsy to move beyond promising research and become part of routine cancer care. Panellists will explore how liquid biopsy assays are informing clinical trial design, what evidence is needed to demonstrate clinical utility, and the practical challenges of implementing these technologies at scale.  

Through a moderated discussion, the panel will debate whether current evidence is sufficient for wider adoption, examine lessons from multi-cancer early detection and other clinical studies, and consider how emerging approaches, including multi-modal liquid biopsy, could shape the future of precision oncology. 

Key Takeaways:

  • Understand how liquid biopsy assays are being used in clinical trial design and execution 
  • Explore key challenges in translating assays into clinically approved tests 
  • Gain insight into how liquid biopsy technologies may be implemented in routine patient care 
  • Discuss how innovations such as fragmentomics and multi-modal analysis could influence the future of precision oncology 

Panellists:

Daniel Stetson, Director of Translational Genomics, AstraZeneca  

Magda Meissner, Clinical Liquid Biopsy Lead, All Wales Medical Genomics Services  

Florent Mouliere, Team Lead, National Biomarker Centre, CRUK Manchester Institute

Hosted by

  • External speaker
    AR E
    Alexandre Rouette
  • External speaker
    JF E
    James Flynn
  • External speaker
    MN E
    Maria Neofytou
  • External speaker
    AR E
    Alexandre Rouette

Front Line Genomics

Delivering the Benefits of Genomics to Patients Faster

Front Line Genomics is a genomics-focused social business, with a mission to deliver the benefits of genomics to patients faster. We organize the Festival of Genomics & Biodata, webinars, reports and smaller boardroom-style strategy meetings.